Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

UCLA Hematology/Oncology - Parkside ( Site 0021), Santa Monica, California, United States

Orchard Healthcare Research Inc. ( Site 0006), Skokie, Illinois, United States

Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003), Billings, Montana, United States

Northwest Cancer Specialists (Compass Oncology) ( Site 8003), Tigard, Oregon, United States

SCRI Oncology Partners ( Site 7000), Nashville, Tennessee, United States

Texas Oncology - DFW ( Site 8000), Dallas, Texas, United States

Houston Methodist Hospital ( Site 0022), Houston, Texas, United States

Virginia Oncology Associates (VOA) ( Site 8001), Norfolk, Virginia, United States

Seoul National University Hospital ( Site 2400), Seoul, South Korea

Severance Hospital, Yonsei University Health System ( Site 2402), Seoul, South Korea

Asan Medical Center ( Site 2401), Seoul, South Korea

Institut Català d'Oncologia (ICO) - Badalona ( Site 1700), Badalona, Catalonia, Spain

Clinica Universidad de Navarra ( Site 1703), Madrid, Madrid, Comunidad de, Spain

Hospital Universitario Reina Sofia ( Site 1702), Córdoba, Spain

Taichung Veterans General Hospital ( Site 2502), Taichung, Taiwan

National Cheng Kung University Hospital ( Site 2503), Tainan, Taiwan

Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501), Taipei, Taiwan